Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Craxi

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Hepatology (Baltimore, Md.)|February 1, 1994
Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatmentS Magrin, A Craxi, C Fabiano, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 17, 2005
Prolonged prothrombin time, Factor VII and activated FVII levels in chronic liver disease are partly dependent on Factor VII gene polymorphismsS Grimaudo, A Craxi, S Gentile, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 8, 2007
Coeliac disease: oral ulcer prevalence, assessment of risk and association with gluten-free diet in childrenG Campisi, C Di Liberto, A Carroccio, et al.
Archives of Gerontology and Geriatrics. Supplement|February 7, 2004
Analysis of hemochromatosis gene mutations in the Sicilian population: implications for survival and longevityC R Balistreri, G Candore, P Almasio, et al.
Journal of Hepatology|July 1, 1989
Detection of hepatitis delta virus RNA in chronic liver diseaseJ Saldanha, F di Blasi, C Blas, et al.
Digestive Diseases and Sciences|May 11, 1999
Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferonP L Almasio, V Di Marco, C Bonura, et al.
The New England Journal of Medicine|November 20, 1998
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy GroupG L Davis, R Esteban-Mur, V Rustgi, et al.
Journal of Viral Hepatitis|October 10, 2012
Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirinS Zeuzem, M Rodríguez-Torres, K Rajender Reddy, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 1, 2004
The rational use of albumin in patients with cirrhosis and ascites. A Delphi study for the attainment of a consensus on prescribing standardsP Gentilini, M Bernardi, L Bolondi, et al.
Journal of Viral Hepatitis|January 14, 2012
Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral responseA Craxi, S Koutsounas, P Ogurtsov, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Hepatology (Baltimore, Md.)|February 1, 1994
Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatmentS Magrin, A Craxi, C Fabiano, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 17, 2005
Prolonged prothrombin time, Factor VII and activated FVII levels in chronic liver disease are partly dependent on Factor VII gene polymorphismsS Grimaudo, A Craxi, S Gentile, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 8, 2007
Coeliac disease: oral ulcer prevalence, assessment of risk and association with gluten-free diet in childrenG Campisi, C Di Liberto, A Carroccio, et al.
Archives of Gerontology and Geriatrics. Supplement|February 7, 2004
Analysis of hemochromatosis gene mutations in the Sicilian population: implications for survival and longevityC R Balistreri, G Candore, P Almasio, et al.
Journal of Hepatology|July 1, 1989
Detection of hepatitis delta virus RNA in chronic liver diseaseJ Saldanha, F di Blasi, C Blas, et al.
Digestive Diseases and Sciences|May 11, 1999
Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferonP L Almasio, V Di Marco, C Bonura, et al.
The New England Journal of Medicine|November 20, 1998
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy GroupG L Davis, R Esteban-Mur, V Rustgi, et al.
Journal of Viral Hepatitis|October 10, 2012
Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirinS Zeuzem, M Rodríguez-Torres, K Rajender Reddy, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 1, 2004
The rational use of albumin in patients with cirrhosis and ascites. A Delphi study for the attainment of a consensus on prescribing standardsP Gentilini, M Bernardi, L Bolondi, et al.
Journal of Viral Hepatitis|January 14, 2012
Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral responseA Craxi, S Koutsounas, P Ogurtsov, et al.
Pageof 6